Results 211 to 220 of about 858,528 (292)

Investor Perceptions of Climate Policy: Insights From the US Inflation Reduction Act

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT This paper provides the first event study evidence on how the Inflation Reduction Act's (IRA) dedicated climate provisions reshaped equity valuations in the US carbon‐intensive sectors. Focusing on environmentally sensitive industries (ESI), we analyze cumulative abnormal returns around the four key IRA milestones in 2022–2023.
Laura Ferraro   +3 more
wiley   +1 more source

Editorial: Advances in PET-CT imaging, vol. II. [PDF]

open access: yesFront Med (Lausanne)
Santo G, Gazzilli M, Dondi F.
europepmc   +1 more source

Motherhood’s immune legacy reshapes the breast for lasting cancer defence

open access: yesImmuno-Oncology and Technology
P. Savas   +3 more
openaire   +1 more source

Climate Stress Testing on European SME Securitised Loans Under Climate Mitigation Scenarios

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Assessing the future impact of climate risks on the probability of default (PD) of small and medium enterprises (SMEs) is challenging due to limited disclosure, policy uncertainty and exposure to physical risks. This paper addresses this gap by integrating macroeconomic variables from the Network for Greening the Financial System (NGFS ...
Luca Zanin, Raffaella Calabrese
wiley   +1 more source

Confronting Biodiversity Risk: Its Role in Shaping Corporate External Financing Choice

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT This paper investigates how biodiversity risk shapes corporate financing decisions. We propose a Financing Hierarchy Distortion framework, arguing that biodiversity risk amplifies information asymmetry and legitimacy costs, thereby pushing firms toward debt‐heavy adjustments.
Yang Zhou   +3 more
wiley   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

open access: yesBiotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy